BACKGROUND: We studied progress in the fight against non-Hodgkin's lymphoma (NHL) in the Netherlands by describing the changes in incidence, treatment, relative survival, and mortality during 1989-2007. PATIENTS AND METHODS: We included all adult patients with NHL [i.e. all mature B-, T-, and natural killer (NK) cell neoplasms, with the exception of plasma cell neoplasms], newly diagnosed in the period 1989-2007 and recorded in the Netherlands Cancer Registry (n=55 069). Regular mortality data were derived from Statistics Netherlands. Follow-up was completed up to 1 January 2009. Annual percentages of change in incidence, mortality, and relative survival were calculated. RESULTS: The incidence of indolent B-cell and T- and NK-cell neoplasms rose significantly (estimated annual percentage change=1.2% and 1.3%, respectively); incidence of aggressive B-cell neoplasms remained stable. Mortality due to NHL remained stable between 1989 and 2003, and has decreased since 2003. Five-year relative survival rates rose from 67% to 75%, and from 43% to 52%, respectively, for indolent and aggressive mature B-cell neoplasms, but 5-year survival remained stable at 48% for T- and NK-cell neoplasms. CONCLUSIONS: In the Netherlands, incidence of indolent mature B-cell and mature T- and NK-cell neoplasms has increased since 1989 but remained stable for aggressive neoplasms. Survival increased for all mature B-cell neoplasms, preceding a declining mortality and increased prevalence of NHL (17 597 on 1 January 2008).
BACKGROUND: We studied progress in the fight against non-Hodgkin's lymphoma (NHL) in the Netherlands by describing the changes in incidence, treatment, relative survival, and mortality during 1989-2007. PATIENTS AND METHODS: We included all adult patients with NHL [i.e. all mature B-, T-, and natural killer (NK) cell neoplasms, with the exception of plasma cell neoplasms], newly diagnosed in the period 1989-2007 and recorded in the Netherlands Cancer Registry (n=55 069). Regular mortality data were derived from Statistics Netherlands. Follow-up was completed up to 1 January 2009. Annual percentages of change in incidence, mortality, and relative survival were calculated. RESULTS: The incidence of indolent B-cell and T- and NK-cell neoplasms rose significantly (estimated annual percentage change=1.2% and 1.3%, respectively); incidence of aggressive B-cell neoplasms remained stable. Mortality due to NHL remained stable between 1989 and 2003, and has decreased since 2003. Five-year relative survival rates rose from 67% to 75%, and from 43% to 52%, respectively, for indolent and aggressive mature B-cell neoplasms, but 5-year survival remained stable at 48% for T- and NK-cell neoplasms. CONCLUSIONS: In the Netherlands, incidence of indolent mature B-cell and mature T- and NK-cell neoplasms has increased since 1989 but remained stable for aggressive neoplasms. Survival increased for all mature B-cell neoplasms, preceding a declining mortality and increased prevalence of NHL (17 597 on 1 January 2008).
Authors: Saskia A M van de Schans; Liza N van Steenbergen; Jan Willem W Coebergh; Maryska L G Janssen-Heijnen; Dick Johan van Spronsen Journal: Haematologica Date: 2013-09-13 Impact factor: 9.941
Authors: Simone Oerlemans; Floortje Mols; Djamila E Issa; J H F M Pruijt; Wim G Peters; Marnix Lybeert; Wobbe Zijlstra; Jan Willem W Coebergh; Lonneke V van de Poll-Franse Journal: Haematologica Date: 2012-08-28 Impact factor: 9.941
Authors: Laura L Hester; Steven I Park; William A Wood; Til Stürmer; M Alan Brookhart; Jennifer L Lund Journal: Cancer Date: 2018-12-11 Impact factor: 6.860
Authors: Meredith S Shiels; Eric A Engels; Martha S Linet; Christina A Clarke; Jianmin Li; H Irene Hall; Patricia Hartge; Lindsay M Morton Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-04-17 Impact factor: 4.254
Authors: Simone Oerlemans; Sophia K Smith; Catherine M Crespi; Sheryl Zimmerman; Lonneke V van de Poll-Franse; Patricia A Ganz Journal: Psychooncology Date: 2012-07-26 Impact factor: 3.894
Authors: Simone Oerlemans; Floortje Mols; Marten R Nijziel; Wobbe P Zijlstra; Jan Willem W Coebergh; Lonneke V van de Poll-Franse Journal: J Cancer Surviv Date: 2014-05-13 Impact factor: 4.442
Authors: Lonneke van de Poll-Franse; Simone Oerlemans; Anne Bredart; Charalampia Kyriakou; Monika Sztankay; Stephan Pallua; Laurien Daniëls; Carien L Creutzberg; Kim Cocks; Sandra Malak; Giovanni Caocci; Stefano Molica; Weichu Chie; Fabio Efficace Journal: Qual Life Res Date: 2017-11-10 Impact factor: 4.147
Authors: Lindy P J Arts; Simone Oerlemans; Lidwine Tick; Ad Koster; Henk T J Roerdink; Lonneke V van de Poll-Franse Journal: Cancer Date: 2018-04-26 Impact factor: 6.860